ARDELYX, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ARDELYX, INC. (ARDX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $7.29 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $7.71, a 47.98% increase year-over-year.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $5.21, a 39.98% decline year-over-year.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $8.68, a 212.23% increase year-over-year.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.78, a 183.67% increase year-over-year.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $5.08, a 36.10% decline from fiscal 2024.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $7.95, a 153.18% increase from fiscal 2023.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.14, a 227.08% increase from fiscal 2022.
- ARDELYX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $0.96, a 85.45% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.29 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $7.71 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $5.08 10-K · filed 2026-02-19 | |||
| 2025-09-30 | $5.02 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $5.00 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $5.21 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $7.95 10-K · filed 2025-02-20 | |||
| 2024-09-30 | $8.20 10-Q · filed 2024-10-31 | |||
| 2024-06-30 | $8.39 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $8.68 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $3.14 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $2.94 10-Q · filed 2023-10-31 | |||
| 2023-06-30 | $2.92 10-Q · filed 2023-08-02 | |||
| 2023-03-31 | $2.78 10-Q · filed 2023-05-03 | |||
| 2022-12-31 | $0.96 10-K · filed 2023-03-02 | |||
| 2022-09-30 | $0.88 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $0.88 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $0.98 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $6.60 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $6.60 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $6.62 10-Q · filed 2021-08-13 | |||
| 2020-12-31 | $6.89 10-K · filed 2021-03-08 | |||
| 2019-12-31 | $2.56 10-K · filed 2020-03-06 | |||
| 2018-12-31 | $6.01 10-K · filed 2019-03-06 | |||
| 2017-12-31 | $11.73 10-K · filed 2019-03-06 | |||
| 2016-12-31 | $11.42 10-K · filed 2019-03-06 | |||
| 2015-12-31 | $19.60 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $24.41 10-K · filed 2017-02-17 | |||
| 2014-09-30 | $13.95 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $13.95 10-Q · filed 2014-08-08 | |||
| 2013-12-31 | $3.42 10-K · filed 2016-03-04 | |||
| 2012-12-31 | $3.46 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |